Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01532336 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis
A Phase 2 study, sponsored by NovaBay Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 500
- Enrollment target
NCT01532336 is a Phase 2 study that has completed, run by NovaBay Pharmaceuticals. The registered enrollment target is 500 participants.
The verdict
NCT01532336, a Phase 2 study, has completed, sponsored by NovaBay Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 500 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one year of age and older with diagnosis of adenoviral conjunctivitis in at least one eye based upon a positive adenovirus test result using the Aden-Detactor Plus kit (Rapid Pathogen Screening, Inc). Subjects will be randomly assigned to receive either NVC-422 or Vehicle.
Interventions
- DRUG NVC-422 Solution, 0.3%
- DRUG NVC-422 Vehicle Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2012-05 |
| Est. Completion | 2014-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01532336
The ClinicalTrials.gov registry entry for NCT01532336 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NovaBay Pharmaceuticals, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NVC-422 Solution, 0.3% is the first listed.
NCT01532336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01532336 about?
NCT01532336 is a clinical study titled "Efficacy and Safety of NVC-422 in the Treatment of Adenoviral Conjunctivitis". The purpose of this study is to evaluate the clinical and microbiological efficacy and safety of NVC-422 compared to vehicle for adenoviral conjunctivitis. Adults and children one year of age and older with diagnosis of adenoviral conjunctivitis in at least one eye based upon a positive adenovirus t...
What is the current status of trial NCT01532336?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 500 participants. The study started on 2012-05. Estimated completion is 2014-08.
What interventions are being tested in trial NCT01532336?
The interventions under investigation include: NVC-422 Solution, 0.3% (DRUG), NVC-422 Vehicle Solution (DRUG).
Who is sponsoring clinical trial NCT01532336?
This trial is sponsored by NovaBay Pharmaceuticals, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.